Summary
The provided claims largely describe general properties/uses/mechanisms of various NSAIDs and celecoxib/acetaminophen, but the FDA label supplied is specifically for aspirin and extended-release dipyridamole capsules (stroke risk reduction). These off-label/unrelated general drug class statements are unsupported by the supplied label excerpts and some are likely contradictory by omission/mismatch to the label’s indicated use.
Category Scores
Accurate Statements
Unsupported Statements
Aspirin (acetylsalicylic acid) is a nonsteroidal anti-inflammatory drug (NSAID).
The supplied label excerpts for aspirin and extended-release dipyridamole capsules do not describe aspirin as an NSAID.
Aspirin inhibits the production of prostaglandins.
No label excerpt provided states aspirin inhibits prostaglandin production.
By blocking prostaglandin production, aspirin reduces pain and inflammation.
The label excerpts provided focus on stroke risk reduction and additive antiplatelet effects; no pain/inflammation mechanism or indications are stated.
Ibuprofen is an NSAID used to treat headaches, muscle aches, and menstrual cramps.
The supplied label is for aspirin and extended-release dipyridamole capsules and contains no information about ibuprofen indications.
Ibuprofen inhibits prostaglandin production to reduce pain and inflammation.
No label excerpt provided addresses ibuprofen or prostaglandin effects.
Naproxen is an NSAID used to treat headaches, arthritis, and other types of pain.
No label excerpt provided addresses naproxen indications.
Naproxen has a longer half-life than ibuprofen.
No label excerpt provided includes comparative pharmacokinetics for naproxen vs ibuprofen.
Acetaminophen does not have anti-inflammatory effects like aspirin or ibuprofen.
No label excerpt provided discusses acetaminophen or comparative anti-inflammatory effects.
Acetaminophen is used to treat headaches, fever, and minor aches and pains.
No label excerpt provided discusses acetaminophen indications.
Acetaminophen works by blocking the production of prostaglandins in the brain to reduce pain perception.
No label excerpt provided discusses acetaminophen mechanism of action or prostaglandins.
Celecoxib is a COX-2 inhibitor.
No label excerpt provided addresses celecoxib.
Celecoxib selectively targets the COX-2 enzyme responsible for producing prostaglandins.
No label excerpt provided addresses celecoxib or COX-2/prostaglandin selectivity.
By inhibiting COX-2, celecoxib reduces pain and inflammation.
No label excerpt provided addresses celecoxib efficacy for pain/inflammation.
Celecoxib does not affect the COX-1 enzyme, which is involved in protecting the stomach lining.
No label excerpt provided addresses celecoxib COX-1 effects or gastric protection mechanisms.
Meloxicam is a long-acting NSAID.
No label excerpt provided addresses meloxicam.
Meloxicam is used to treat chronic pain, arthritis, and other types of pain.
No label excerpt provided addresses meloxicam indications.
Meloxicam has a longer half-life than ibuprofen.
No label excerpt provided includes half-life comparisons involving meloxicam.
Ketoprofen is a potent NSAID used to treat severe pain, including headaches and arthritis.
No label excerpt provided addresses ketoprofen indications.
Ketoprofen inhibits prostaglandin production to reduce pain and inflammation.
No label excerpt provided addresses ketoprofen or prostaglandin production.
Diclofenac is a topical NSAID applied directly to the skin.
No label excerpt provided addresses diclofenac dosage forms or topical use.
Diclofenac treats localized pain.
No label excerpt provided addresses diclofenac efficacy for localized pain.
Diclofenac is used to treat muscle and joint pain.
No label excerpt provided addresses diclofenac indications.
Diclofenac is used for skin conditions like psoriasis.
No label excerpt provided addresses diclofenac for psoriasis.
Indomethacin is a potent NSAID used to treat severe pain, including headaches and arthritis.
No label excerpt provided addresses indomethacin indications.
Indomethacin inhibits prostaglandin production to reduce pain and inflammation.
No label excerpt provided addresses indomethacin or prostaglandin production.
Piroxicam is a long-acting NSAID.
No label excerpt provided addresses piroxicam.
Piroxicam is used to treat chronic pain, arthritis, and other types of pain.
No label excerpt provided addresses piroxicam indications.
Piroxicam has a longer half-life than ibuprofen.
No label excerpt provided includes half-life comparisons involving piroxicam.
Fenoprofen is a potent NSAID used to treat severe pain, including headaches and arthritis.
No label excerpt provided addresses fenoprofen indications.
Fenoprofen inhibits prostaglandin production to reduce pain and inflammation.
No label excerpt provided addresses fenoprofen or prostaglandin production.
Flurbiprofen is a potent NSAID used to treat severe pain, including headaches and arthritis.
No label excerpt provided addresses flurbiprofen indications.
Flurbiprofen inhibits prostaglandin production to reduce pain and inflammation.
No label excerpt provided addresses flurbiprofen or prostaglandin production.
Ketorolac is a potent NSAID used to treat severe pain, including headaches and arthritis.
No label excerpt provided addresses ketorolac indications.
Ketorolac inhibits prostaglandin production to reduce pain and inflammation.
No label excerpt provided addresses ketorolac or prostaglandin production.
Nabumetone is a long-acting NSAID.
No label excerpt provided addresses nabumetone.
Nabumetone is used to treat chronic pain, arthritis, and other types of pain.
No label excerpt provided addresses nabumetone indications.
Nabumetone has a longer half-life than ibuprofen.
No label excerpt provided includes half-life comparisons involving nabumetone.
Oxaprozin is a long-acting NSAID.
No label excerpt provided addresses oxaprozin.
Oxaprozin is used to treat chronic pain, arthritis, and other types of pain.
No label excerpt provided addresses oxaprozin indications.
Oxaprozin has a longer half-life than ibuprofen.
No label excerpt provided includes half-life comparisons involving oxaprozin.
Sulindac is a potent NSAID used to treat severe pain, including headaches and arthritis.
No label excerpt provided addresses sulindac indications.
Sulindac inhibits prostaglandin production to reduce pain and inflammation.
No label excerpt provided addresses sulindac or prostaglandin production.
Aspirin and ibuprofen are both NSAIDs.
No label excerpt provided defines ibuprofen as an NSAID or supports a statement comparing NSAID status across both.
Aspirin has anti-inflammatory effects while ibuprofen does not.
No label excerpt provided compares aspirin vs ibuprofen anti-inflammatory effects.
COX-2 inhibitors like celecoxib may increase the risk of cardiovascular events.
No label excerpt provided addresses celecoxib or COX-2 inhibitor cardiovascular risk.
COX-2 inhibitors like celecoxib may increase the risk of gastrointestinal bleeding.
No label excerpt provided addresses celecoxib or COX-2 inhibitor GI bleeding risk.
Topical NSAIDs like diclofenac can be effective for localized pain.
No label excerpt provided addresses diclofenac topical products or localized pain efficacy.
Contradictions
Important Omissions
For the supplied labeled product (aspirin and extended-release dipyridamole capsules), the FDA label indicates use is to reduce stroke risk in patients with transient ischemia of the brain (TIA) or completed ischemic stroke due to thrombosis, and provides specific dosing (one capsule orally twice daily) and administration instructions (swallow whole). These labeled points are not mentioned at all.
Importance:
Moderate
Label-specific safety information (e.g., increased bleeding risk) is not addressed in the claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The claims predominantly make broad mechanism/indication statements about many other analgesics (ibuprofen, naproxen, acetaminophen, celecoxib, etc.) that are not supported by the provided prescribing information for aspirin/extended-release dipyridamole capsules. Such unsupported information could mislead users about indications or mechanisms and does not reflect the actual labeled indication and dosing.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are unrelated to the specific FDA-approved label provided (aspirin and extended-release dipyridamole capsules) and are unsupported by the label excerpts.
Suggested Improvement
Restrict claims to what is present in the supplied label: indication (reduce stroke risk in specified patients), dosing (1 capsule twice daily; swallow whole; with/without food), and label-supported safety statements (e.g., increased bleeding risk, contraindication in NSAID-allergic patients with aspirin-exacerbated respiratory disease). Avoid general NSAID/analgesic class mechanism and half-life comparisons unless explicitly supported in the label.